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1. Introduction 
Hypertension is common in patients with advanced stages of chronic kidney disease (CKD) 
and its prevalence remain very high in patients with end stage renal disease (ESRD) treated 
with hemodialysis. Using various definitions of hypertension, the prevalence of 
hypertension in hemodialysis patients is up to 90%. The diagnosis of hypertension in 
hemodialysis patients is often complicated especially because there are large swings in 
blood pressure with dialysis and it is difficult to accurately ascertain the blood pressure in 
the interdialytic period.  
The pathogenesis of hypertension in hemodialysis patients is multilayered and at present 
still not completely elucidated. One or more of the factors play a role in a individual patient 
– hypervolemia, increased sympathetic activity, erythropoietin, altered endotelial cell 
function and many others. 
Poorly controlled hypertension is a risk factor for cardiovascular disease, congestive heart 
failure, and cerebrovascular disease in the general population. The influence of 
hypertension on cardiovascular outcomes in hemodialysis patients is less clear, and 
complicated because of the high prevalence of comorbid conditions in these patients. The 
management of hypertension is difficult in hemodialysis patients, because there is a 
significant difference in blood pressure between the pre-, post- and interdialytic period. The 
best timing and method of blood pressure measurement in hemodialysis patients is still 
uncertain. The blood pressure variability and extreme changes of the volemic state make it 
difficult to obtain a truly representative value of blood pressure in hemodialysis patients if 
based only on an isolated blood pressure measurements in dialysis center. There are many 
differences related to technique of blood pressure measurement, timing of measurement in 
relation to hemodialysis session, and reliance on the use of home blood pressure 
measurements or ambulatory blood pressure monitoring (ABPM). Casual conventional 
sphygmomanometry blood pressure measurements at home and in dialysis center are far 
from being ideal to reflect blood pressure levels precisely in hemodialysis patients and 
adjusting antihypertensive treatment according to casual blood pressure measurements may 
cause an inadequate blood pressure control.  
ABPM is the most reproducible method of blood pressure measurement in hemodialysis 
patients, and most would argue that it should be used as the gold standard for the definition 
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of hypertension in ESRD. ABPM has also been used to better define the relationship 
between blood pressure, target organ damage, and outcomes in patients with CKD and 
ESRD. ABPM has been shown to predict cardiovascular events better than conventional 
blood pressure measurement in patients with essential hypertension. Although many 
patients received antihypertensive drugs, only small percent have adequately controlled 
blood pressure. There are many reasons for this problem. 
The purpose of this chapter is to discuss about the pathogenesis of hypertension, definition 
of hypertension, optimal time and target blood pressure, different methods of blood 
pressure measurements, discuss the relationship between blood pressure and 
cardiovascular outcomes and – finally outline the therapies to control blood pressure in 
hemodialysis population. 
2. Pathogenesis of hypertension in end stage renal disease 
Several of the generally accepted pathogenetic factors that may be involved in the 
development of hypertension in ESRD and CKD are listed in Table 1. These will be 
discussed separatelly.  
2.1 Sodium and volume excess 
The normal physiologic response to intravascular volume expansion in the healthy person is 
to increase glomerular filtration via a rise in cardiac output, enhance urinary sodium 
excretion by supression of the renin-angiotensin-aldosterone system, and increase 
natriuresis as a result of the effects of atrial natriuretic peptide and an endogenous digitalis-
like factor. The result of these physiologic adaptations is natriuresis and diuresis, and 
restoration of normal plasma volume. In contrast, excess extracellular fluid volume and 
increases in total body exchangeable sodium are common in patients with ESRD, because of 
diminished sodium and fluid excretory capacity. It has been shown that normotensive 
patients have significantly less total body water than hypertensive hemodialysis patients, 
demonstrating the importance of intravascular volume in the pathogenesis of hypertension 
in patients with ESRD (Lins et al, 1997).  
 
 
    Sodium and volume excess 
    Increased sympathetic activity 
        Activation of the renin – angiotensin - aldosterone system due to primary vascular 
disease or  regional ischemia induced by scarring 
    Erythropoietin administration 
        An increase in endothelium-derived vasoconstrictors (endothelin) or a reduction of   
endothelium-derived vasodilators (nitric oxide) 
    Parathyroid hormone excess secretion 
    Renal vascular disease 
    Worsening of preexisting essential hypertension 
    Reduced production of prostaglandins/bradykinins 
 
Table 1. Putative Pathogenetic Mechanisms of Hypertension in ESRD patients. 
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Overhydration and sodium retention plays a role not only by volume overload, but also by 
nonhemodynamic direct effects on the left ventricle and vascular system. The patients at 
greatest risk in a vicious cycle (fluid overload → problems in removing fluid → further fluid 
overload) are those who begin dialysis with low predialysis blood pressures as the result of 
severe cardiac failure. The prognosis of these patients is very poor because fluid can be 
removed only very slowly in such patients. To further aggravate this situation, dialysis 
patients often have diastolic dysfunction. In these patients, even a small decrease in filling 
pressure following dialysis ultrafiltration may result in decreased cardiac output and 
hypotension. As a result, fluid accumulation progresses inexorably. In addition, autonomic 
neuropathy complicating uremia and diabetes with inadequate peripheral arteriolar tone 
reactivity further increases the risk that hypotension occurs when the patient is still fluid 
overloaded. While the importance of salt regulating fluid balance by dietetic means and 
avoidance of sodium loading during dialysis has received major emphasis, sodium has also 
been proposed as a uremic toxin with specific effects stimulating oxidative stress. Possibly 
related to this is the finding that excess sodium may be stored nonosmotically at 
concentrations of 180 to 190 mEq/L in skin, connective tissue, cartilage, and bone, possibly 
bound to glucosoaminoglycans. Under various circumstances, this sodium could be 
intermittently released into the circulation causing hypervolemia and oxidative stress. 
Control of volume status can either normalize the blood pressure or make the hypertension 
easier to control in the great majority of dialysis patients. Volume status of ESRD patients 
influences both pre- and postdialysis blood pressure. Volume status is perhaps the most 
important factor in the development and maintenance of hypertension in dialysis patients 
(Mailloux & Haley, 1998). Volume expansion leads to an elevation in blood pressure 
through the combination of an increase in cardiac output and an inappropriately high 
systemic vascular resistance. Numerous authors described a correlation between 
hypertension and hypervolemia in dialysis patients, since hypervolemia is the cause of 
hypertension in up to 90% of dialysis patients (De Leeuw, 1994, Katzarski et al, 1997, 
Kirchner, 1997, Luik et al, 1998, Özkahya et al, 1999, Remuzzi, 1999, Agarwal et al, 2011). 
Also our study with 86 included hemodialysis patients confirmed this as well (Ekart & Hojs, 
2006). Estimation of excess of volume is dependent upon estimation of dry weight. In a 
dialysis patient, dry weight is that body weight at the end of dialysis at which the patient 
can remain normotensive until the next dialysis despite the retention of salt water (saline). 
Dry weight varies over time as lean body mass and body fat change. At dry weight, the 
extracellular volume is at or near normal but not less than normal (Charra et al, 1996). An 
incorrect estimation of dry weight will lead either to chronic fluid overload or chronic 
underhydration. The blood pressure should remain in the normal range during the whole 
interdialytic period. If the patient remains hypertensive after a dialysis or becomes 
hypertensive before the next dialysis, he is, by definition, above his dry weight (Charra et al, 
1996). The postdialysis body weight should ideally reflect a state of normohydration. The 
assessment of dry weight is usually based on clinical observations, such as weight gain, 
blood pressure, jugular venous pressure, presence of edema, congestion, and chest X-ray 
parameters (Cheriex et al, 1989, Katzarski et al, 1997). These methods are not very reliable, 
and a more accurate, objective, non-invasive assessment of optimal dry weight is therefore 
mandatory. The diameter of the inferior vena cava may be used to evaluate the volume state 
and serve as a guideline for assessing dry weight. Inferior vena cava diameter measured in 
expiration just below the diaphragm in the hepatic segment in patients lying in a supine 
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position, correlated well with central venous pressure (Figure 1). Inferior vena cava 
diameter, corrected for body surface area between 8.0 and 11.5 mm/m2, was considered to 
represent normovolemia (Cheriex et al, 1989). The collapse index was defined as (maximal 
diameter on expiration minus minimal diameter on deep inspirationdivided by maximal 
diameter on expiration) times 100 (Figure 2 & 3). Hypervolemia (mean right atrial pressure 
> 7 mmHg) was defined as a collapse index of less than 40% and/or inferior vena cava 
diameter of above 11.5 mm/m2. Hypovolemia (mean right atrial pressure < 3 mmHg) was 
defined as a inferior vena cava diameter of less than 8 mm/m2 and/or collapse index of 
more than 75% (Cheriex et al, 1989). In patients with severe valvular and pulmonary 
disease, and patients in whom there is an increased inthrathoracic or intrabdominal 
pressure, these measurements are unreliable. Unfortunately, one problem with a reliance 
upon a clinical assessment of volume status is that volume expansion may persist even 
among those thought to have attained dry weight. The timing of the postdialysis inferior 
vena cava diameter measurement is critical. During hemodialysis, ultrafiltrated fluid is 
primarily removed from the circulating blood volume, which is refilled by fluid from the 
interstitial space. Since this process does not occur instantaneously, a state of disequilibrium 
follows hemodialysis, during which refilling continues and blood volume increases until 
equilibrium is attained; this must be taken into account when using inferior vena cava 
diameter to assess dry weight. The lowest values of inferior vena cava diameter were found 
immediately at the end of hemodialysis, followed by an increase during the following 2 
hours due to refilling of the plasma volume from the interstitial space (Katzarski et al, 1997). 
Thus, it seems doubtful that measurements of inferior vena cava diameter within 2 hours 
after hemodialysis reliably reflect the state of hydration.  
 
 
Fig. 1. Ultrasound determination of inferior vena cava (IVC) diameter; RA=right atrium. 
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Fig. 2. Inferior vena cava diameter through the respiratory cycle using M mode. 
 
 
Fig. 3. Inferior vena cava diameter variations with the respiratory cycle. 
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This is especially true if the duration of hemodialysis is short and the ultrafiltration rate is 
rapid. It appears that inferior vena cava diameter before hemodialysis may be useful as an 
indicator of extracellular fluid overload. Inferior vena cava diameter measured at the end or 
shortly after hemodialysis may be misleading in assessing dry weight (Katzarski et al, 1997). 
Among hemodialysis patients a period of time must ensue between the attainment of dry 
weight and adequate control of blood pressure, a property termed the lag phenomen 
(Charra et al, 1998). In clinical practice, the dry weight is usually established by a 
progressive decrease in the post-dialysis body weight, usually over a 4-8 week period after 
the initiation of maintenance hemodialysis (Chazot et al, 1999). Acquired cystic kidney 
disease (ACKD) and hypertension are frequent complications of CKD. ACKD is a result of 
CKD, its prevalence and grade depending on the duration of CKD and dialysis treatment. 
We know that renal cysts are present prior to hemodialysis treatment in approximately one 
third of all patients. The prevalence of ACKD described in hemodialysis patients lies 
between 35 and 79% (Ishikawa, 1991). So far the literature offers only few data to clarify 
whether hypertension is also a possible complication of ACKD. Described are individual 
clinical cases of hypertension in patients with simple renal cysts. Some studies established a 
connection between simple renal cysts and hypertension in a large number of patients with 
normal renal function (Pedersen et al, 1993, 1997, Ekart et al, 2001). The question of whether 
perhaps ACKD is also involved in the pathogenesis of hypertension in hemodialysis 
patients and whether hypertension is also a complication of ACKD remains open. Hardly 
any studies dealing with this specific topic are to be found while the results of available 
studies do not clarify the likely involvement of ACKD in the development of hypertension 
in hemodialysis patients. The aim of our published study was to establish the prevalence 
and the grade of ACKD in patients on renal replacement therapy with hemodialysis, the 
frequency of hypertension in these patients as well as the possible connection between the 
presence of ACKD and hypertension in hemodialysis patients (Ekart & Hojs, 2006). In the 
study 86 hemodialysis patients (46 males and 40 females; mean age 51.3 years; mean 
duration of hemodialysis treatment 55.3 months) were included. Their native kidneys were 
examined with an ATL-HDI 3000 ultrasound device (2-4 MHz convex probe). Depending on 
the number of cysts in the kidney, the manifestations were divided into three grades: grade 
0: no cysts; grade 1: less than ten cysts in both kidneys; grade 2: more than ten cysts in both 
kidneys. Blood pressure was measured 30 minutes before and after hemodialysis. Mean 
one-month values were analyzed. Hypertension was defined as systolic blood pressure of ≥ 
150 mmHg, diastolic blood pressure of ≥ 90 mmHg and/or antihypertensive treatment. The 
diameter of the inferior vena cava (indicator of dry weight) was measured with the same 
ultrasound device as the kidneys 3 hours after hemodialysis. ACKD was present in 48 
(55.8%) patients, there was no statistically significant difference regarding sex. 24 (50%) 
patients had grade 1 ACKD and 24 (50%) grade 2 ACKD. 68 (79.1%) patients suffered from 
hypertension, which was statistically significantly more common in male patients (p=0.048). 
In 68 (79.1%) patients hypertension was detected before hemodialysis and in 54 (62.8%) 
patients also after hemodialysis. 39 (45.3%) patients suffered simultaneously from ACKD 
and hypertension; 22 (56.4%) of them were males and 17 (43.6%) females. No statistically 
significant correlation between hypertension and ACKD was established. The prevalence 
and grade of ACKD were statistically significantly associated with the duration of dialysis 
treatment (p<0.01). Multiple regression analysis detected a significant correlation only 
between hypertension and the diameter of the inferior vena cava (p<0.05). Prevalence and 
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grade of ACKD increase with the duration of dialysis treatment. ACKD was not associated 
with hypertension. There was a correlation between the diameter of the inferior vena cava as 
a factor of circulating fluid volume and hypertension in hemodialysis patients (Ekart & 
Hojs, 2006).  
2.2 Increased sympathetic activity 
Sympathetic activity is a common finding in ESRD, correlating with the increase in both 
vascular resistance and systemic blood pressure (Converse et al, 1992). Investigators have 
demonstrated that sympathetic activity is increased in those patients on chronic 
hemodialysis who still have their native kidneys. Sympathetic nerve activity was found to 
be normal in hemodialysis patients with bilateral nephrectomy, leading to the hypothesis 
that sympathetic overactivity in uremia is caused by a neurogenic signal (carried by renal 
afferents) arising in the failing kidney (Augustyniak et al, 2002). This hypothesis is 
supported by rat studies showing that renal deafferentation abrogates hypertension in the 
5/6 nephrectomy model of chronic renal insufficiency. In addition, in patients with chronic 
renal insufficiency and renin-dependent hypertension, sympathetic overactivity was 
normalized by chronic angiotensin converting enzyme inhibition but not by calcium channel 
blockade, implicating a major central neural action of angiotensin II. Factors such as renal 
ischemia, chronic inflammation, oxidative stress, obesity, nocturnal hypoxia, and elevated 
plasma levels of asymmetric di-methyl-arginine (ADMA) may contribute to increased 
sympathetic activity (Levin et al, 2010). 
2.3 Activation of the renin – angiotensin - aldosterone system 
Although many patients may have plasma renin activity in the normal range, 
inappropriately increased plasma renin activity in relation to exchangeable sodium has long 
been recognized in uremic patients with hypertension (Kornerup et al, 1984). That the renin-
angiotensin system is activated even in hemodialysis patients is illustrated by the fact that 
renin is increased with ultrafiltration dialysis (Henrich et al, 1977) and infusion of 
angiotensin II antagonist, improves blood pressure. Furthermore, patients treated with the 
angiotensin-converting enzyme inhibitor lisinopril have a dose-dependent increase in 
plasma renin activity and an improvement in blood pressure (Agarwal et al, 2001). Patients 
whose blood pressure is not controlled by maintenance of dry weight have increased plasma 
renin activity and demonstrate a dramatic improvement in hypertension control after 
interruption of the renin-angiotensin axis by bilateral nephrectomy (Bellinghieri et al, 1999). 
2.4 Erythropoietin 
Hypertension is a common adverse effect of erythropoietin therapy. It occurs more 
commonly in those people with preexisting hypertension, a positive family history of 
hypertension, rapid correction of anemia, or with severe anemia (Ishimitsu et al, 1993, Lebel 
et al, 1994, Bellinghieri et al, 1999). Nearly one third of renal failure patients treated with 
erythropoietin develop an increase in blood pressure of 10 mmHg or more (Eschbach et al, 
1989). Although the exact mechanism by which erythropoietin increases blood pressure is 
not known, it may involve reduced nitric oxide activity due to scavenging by hemoglobin, 
increase in whole blood viscosity (Koppensteiner et al, 1990), and increased vascular 
reactivity to norepinephrine (Hand et al, 1995) or other mechanisms (Bode-Boger et al, 1996). 
There also may be more hypertension associated with the intravenous route of 
administration and larger dose ranges. 
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2.5 Endothelium – derived factors 
The endothelium plays an important role in the regulation of vasomotor tone. Endothelin-1, 
an endothelium-derived peptide with vasoconstrictive and mitogenic effects on smooth 
muscles, is involved in vascular tone regulation and in the pathogenesis of atherosclerosis 
(Stefanidis et al, 2004). Elevated plasma levels of endothelin-1 have been found in uremic 
patients. The concentrations of other endothelin isoforms also may be increased, but only 
endothelin-1 has been linked to the high blood pressure. Endothelium-derived nitric 
oxyde plays a critical role in the maintenance and regulation of vascular tone and modulates 
key processes mediating vascular disease, including leukocyte adhesion, platelet 
aggregation, and vascular smooth muscle proliferation (Furchgott, 1996). The endothelium 
also produces potent vasodilators, such a prostacycline and nitric oxide. Endothelial nitric 
oxide synthase enzymatically produces nitric oxide from the substrate L-arginine. L-
arginine supplementation can partially reverse renal failure – associated endothelial 
dysfunction. A circulating inhibitor of nitric oxide synthase, ADMA, competes with L-
arginine for nitric oxide synthase. In humans with salt-sensitive hypertension, 
administration of a high-salt diet increases plasma ADMA and blood pressure (Fujiwara et 
al, 2000). Circulating ADMA is increased in subjects with CKD (Vallance et al, 1992) and 
ESRD (Mallamaci et al, 2004) and may contribute to endothelial dysfunction and increased 
blood pressure. In ESRD patients, ADMA is a death predictor (Aucella et al, 2009) and is 
correlated with increased left ventricular thickness and reduced ejection fraction, consistent 
with its ability to increase systemic vascular resistence (Zoccali et al, 2002). Oxidative stress 
leads to the accumulation of ADMA and promotes endothelial dysfunction. Inflammation, 
increased homocysteine levels, reduced antioxidant defenses, and increased free radicals in 
ESRD may therefore provide an explanation for the relationship between oxidative stress, 
endothelial dysfunction, and the generation of hypertension. 
2.6 Parathyroid hormone excess secretion 
There may be a correlation between an increase in intracellular calcium levels induced by 
parathyroid hormone excess and hypertension. Calcium entry into smooth muscle cells of 
the blood vessels can lead to vasoconstrition and hypertension. Some observations linking 
the correction of hyperparathyroidism by either vitamin D administration or 
parathyroidectomy in chronic dialysis patients, resulting in a lower blood pressure, have 
supported this hypothesis. In one small series, administration of alfacalcidiol, a vitamin D 
analogue, to treat hyperparathyrodism resulted in significant decreases in levels of 
parathyroid hormone, platelet intracellular calcium, and mean blood pressure (Raine et al, 
1993). 
2.7 Renal vascular disease 
Ischemic renal disease is defined as a clinically important reduction in glomerular filtration 
rate (GFR) or loss of renal parenchyma caused by hemodynamically significant renal artery 
stenosis. Many patients with a presumed diagnosis of hypertensive nephrosclerosis actually 
have undiagnosed ischemic nephropathy as the etiology of their ESRD. It is important for 
the clinician to identify ischemic renal disease, because ischemic renal disease is a 
potentially reversible cause of chronic renal failure in a hypertensive patient. Atherosclerotic 
renal artery disease is common among patients with coronary artery disease and aortic and 
peripheral vascular disease. Atherosclerotic renal artery disease is a progressive disorder, 
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and its progression is associated with loss of renal mass and functioning (Preston & Epstein, 
1997). In a review of hypertension in ESRD patient, the diagnosis of ischemic nephropathy 
and renal vascular disease should not be overlooked.  
2.8 Reduced production of prostaglandins/bradykinins 
The kidneys produces several vasodilating substances such as kinins, prostaglandins, or 
antihypertensive neural renomedullary lipids, and decreased production and activity of 
these substances could play a role in the pathogenesis of hypertension. Indeed, decreased 
blood levels of vasodilating prostaglandin PgE2 have been observed in hypertensive ESRD 
patients, and a negative correlation between the prostacyclin metabolite 6-keto-PgF1 and 
blood pressue has been observed in uremic patients. 
3. Time of measurement of blood pressure, definition, and meaning of 
hypertension in hemodialysis patients 
3.1 When should blood pressure be measured? 
The prevalence of hypertension in hemodialysis patients is very high: in the time of 
progression from different stages of CKD to ESRD is between 40 and 90% (Salem, 1995, 
Agarwal & Lewis, 2001, Agarwal, 2002). Despite this high prevalence, there is limited 
knowledge about how to manage it in hemodialysis patients. Blood pressure variability is 
present in all people but is particularly prevalent in hemodialysis patients. This greater 
variability is related to the following: changes in volume status, change of sympathetic 
activity, hypotensive episodes during hemodialysis, antihypertensive drugs concentration 
and their dialyzability, erythropoietin, renin-angiotensin-aldosterone system activation, 
secondary hyperparathyroidism and other factors. Unlike the general population, for which 
there is a clear consensus of how to measure blood pressure and the blood pressure goal 
that is needed to reduce risk, this is not the case for people who receive renal replacement 
therapy. Moreover, in the patient with ESRD, a consensus for how to measure blood 
pressure has not been reached. In hemodialysis patients we can see blood pressure changes 
during hemodialysis in the dialysis center and in the interdialytic period. Which blood 
pressure should be taken to signify hypertension is more pertinent in dialysed individual 
than in the general population because of their fluctuating fluid status and other factors 
associated with the hemodialysis session. In the general hypertensive population it is known 
that the use of single measurements as a reliable indicator of the overall blood pressure 
control is fraught with difficulty because of transient and persistent elevations of pressure in 
clinical settings (Mezzeti et al, 1997). The variability of casual measurements in relation to 
the dialysis cycle confound management decisions and pose a dilemma with regard to the 
optimum timing and method of blood pressure measurement in this setting. Treatment 
decisions are mostly based on pre-dialysis blood pressure measurements. However the 
relevance of these measurements has been questioned. Several options exist for blood 
pressure measurement in hemodialysis patients, such as pre- or post-dialysis blood 
pressure, ABPM, and interdialytic home blood pressure. There is a marked difference in 
blood pressure between the pre-, post- and interdialytic period. It is unclear as to which time 
of blood pressure measurement best reflects the burden of hypertension and correlates best 
with cardiovascular outcomes (Rahman, 2005). Pre-dialysis blood pressure often 
overestimated basal blood pressure while post-dialysis blood pressure underestimated it, 
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although the latter is closer to the basal blood pressure value. Blood pressure variability pre-
dialysis, post-dialysis and in interdialytic period is the reason for different conclusions in the 
studies – studies concluded, that the most important and representative are pre-dialysis 
(Conion et al, 1996, Agarwal, 1999), post-dialysis blood pressure measurements (Kooman et 
al, 1992, Mitra et al, 1999), in other study there were most representative the combination of 
pre- and post-dialysis blood pressure values (Coomer et al, 1997).  
It is well known »white-coat effect«, which is defined as transient rise in blood pressure that 
occurs in the clinical settings (Myers et al, 1997). ABPM is required for the diagnosis of the 
white-coat effect. Mitra et al compared interdialytic ABPM with blood pressure obtained in 
hemodialysis patients at arrival to the dialysis center, after 10 minutes of rest in a quiet 
room, and at other time points (Mitra et al, 1999). White-coat effect was defined as the rise in 
blood pressure of > 20/10 mmHg in the reading on attendance to the dialysis center above 
the daytime ambulatory blood pressure during the 6 hours prior to attending the dialysis 
center (Mitra et al, 1999). White-coat effect was observed in 41% patients at arrival to 
dialysis center and this effect did not persist throughout the dialysis session (Mitra et al, 
1999). The timing of the dialysis session did not influence the presence of white-coat effect, 
which persists even in patients on antihypertensive therapy (Mitra et al, 1999). The white-
coat effect may be more common in renal patients than in the general hypertensive 
population perhaps due to an exaggerated sympathetic response conditioned by uremia 
(Rosansky et al, 1995). The timing of casual pre-dialysis and post-dialysis blood pressure 
measurement is crucial. Both can be biased by the dialysis procedure itself. The traditional 
diagnosis of hypertension based solely on pre-dialysis clinic measurements can lead to gross 
overestimation attributable to a white-coat effect. The best single approximation of 
interdialytic blood pressure is the 20-min post-dialytic measurement (Mitra et al, 1999). 
Canella and associates have pointed out that »false normotensive classification to subjects 
who are actually hypertensive, may possibly cause the link between arterial hypertension 
and left ventricular hypertrophy to be missed« (Canella et al, 2000). Those patients who 
have normal blood pressure in the dialysis center, but increased blood pressure outside the 
dialysis center as assessed by ABPM have »masked hypertension«. In an elderly population 
of patients with essential hypertension but without kidney disease, 9% were found to have 
masked hypertension (Bobrie et al, 2004). The cardiovascular prognosis of such patients is 
similar to that of poorly controlled hypertensives. The causes of masked hypertension in the 
dialysis population are not known. However, sleep apnea, which commonly occurs in 
hemodialysis patients, may be an important cause of masked hypertension. Sleep apnea 
causes a nocturnal increase in blood pressure, the magnitude of which increases with the 
severity of sleep apnea (Zoccali et al, 1998). The daytime blood pressure in these patients 
may not be elevated or may not accurately reflect the cardiovascular burden of 
hypertension; ABPM may be of particular value in assessing cardiovascular risk in such 
individuals. Hemodialysis blood pressure measurement and ABPM correlation is poor. A 
recent meta-analysis showed that pre- and post-dialysis blood pressure measurements are 
imprecise estimates of interdialytic ambulatory blood pressure (Agarwal et al, 2006a). In this 
meta-analysis median pre-dialysis systolic blood pressure and diastolic blood pressure were 
8.6 and 2.6 mmHg higher than ABPM, respectively. In a single-center cross-sectional study, 
1-week-averaged home systolic blood pressure was similar to interdialytic ABPM and 
superior to pre- and post-dialysis blood pressure in predicting left ventricular hypertrophy; 
diastolic blood pressure was not associated with left ventricular hypertrophy (Agarwal et al, 
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2009a). In an earlier study, ABPM added minimal information to the prediction of left 
ventricular hypertrophy, compared with the average of 12 routine pre-dialysis blood 
pressure measurements (Zocalli et al, 1999). Although a worthy goal, neither measurement 
of ABPM nor self-measured home blood pressure may be feasible for most patients 
throughout the world, leaving pre-dialysis and post-dialysis blood pressure measurements 
to be used, but with caution and with the knowledge that these are inferior (Levin et al, 
2010). 
3.2 Target blood pressure and what blood pressure level defines hypertension in 
chronic hemodialysis patients 
There is still no consensus about whether to lower increased blood pressure in hemodialysis 
patients or the level to which blood pressure should be targeted (Agarwal, 2005, Foley & 
Agarwal, 2007). Hypertension is common and difficult to control and define in ESRD 
patients undergoing hemodialysis. ESRD patients are most frequently characterized by an 
increased systolic blood pressure with diastolic blood pressure within the normal range (<90 
mm Hg) or even lower, resulting in increased pulse pressure. The increased systolic blood 
pressure is already found in young hemodialysis population. Diastolic blood pressure is 
usually higher in younger hemodialysis patients and declined with advancing age. All these 
changes result in a blood pressure pattern close to that observed in older subjects in general 
populations, i.e., isolated (or predominant) systolic hypertension, and attributable to 
»accelerated ageing« in ESRD. The definition of blood pressure targets and normotension in 
ESRD is not defined and in the absence of prospective controlled interventional studies, 
values accepted for general populations (<140/90 mm Hg) cannot be extrapolated to uremic 
patients.  
In ESRD patients consensus to which level blood pressure should be reduced has not been 
reached. For definition and treatment of hypertension in hemodialysis patients, we need to 
know exactly blood pressure measurements. To evaluate blood pressure fluctuations better 
over the 2-days period (on the hemodialysis and on interdialytic day), ABPM is the gold 
standard to define a hemodialysis patient`s blood pressure. ABPM can provide information 
during sleep and early morning awakening, when blood pressure and cardiovascular risk 
are highest (Hopkins & Bakris, 2009a). In the general population, ABPM provided a more 
accurate prediction of cardiovascular outcomes than office blood pressure (Levin et al, 2010). 
Blood pressure levels defining the presence or absence of hypertension differ with the use of 
pre-dialysis, post-dialysis, self-measured home blood pressure, and ABPM. The recent 
National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines suggest 
that pre-dialysis and post-dialysis blood pressure should be <140/90 and <130/80 mmHg, 
respectively (K/DOQI Workgroup, 2005). These targets were largely based on the expert 
judgment of the workgroup, applying weak evidence. Future research will decide whether 
the definition of hypertension on the basis of home blood pressure should be the same as 
that for the general population, as outlined in the Seventh Report of the Joint Natonal 
Committee (JNC 7) (Chobanian et al, 2003), with systolic blood pressure > 139 mmHg or 
diastolic blood pressure > 89 mmHg. In summary, the target goals should be realized upon 
individual patient. In some younger patients, the target blood pressure may even be set as 
low as 120/80 mmHg. 
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4. Blood pressure measurement in hemodialysis patients 
In patients with ESRD, routine clinic and dialysis center blood pressure measurements may 
be poor indicators of blood pressure control. Patients on hemodialysis typically do not have 
their blood pressure measured under standardized conditions, a source of error in the 
assessment of their blood pressure. There are some unique sources of error involving 
interdialytic weight gain, occurence of sleep apnea and consequent nocturnal hypertension, 
inability to take blood pressure in both arms in patients who have hemodialysis angioaccess 
in the arm, and the white coat effect in these patients as well (Agarwal, 2002). Although 
blood pressure is measured frequently in the dialysis treatment enviroment, the technical 
aspects are often unsatisfactory. The recommendation for measuring blood pressure in the 
general population includes the patient´s sitting quietly upright in a chair for approximately 
5 min with the arm supported at heart level. In addition, an appropriately fitting 
sphygmomanometer cuff is recognized as vital to accurate readings (Chobanian et al, 2003). 
Conversely, there remains disagreement concerning the utility and reproducibility of such 
method in hemodialysis patients. In most studies of ESRD patients, dialysis center 
measurements were used to explore the relationship between hypertension and 
cardiovascular events. However, dialysis center measurements fail to accurately 
characterize blood pressure in ESRD patients on hemodialysis, making it difficult to define 
the prognostic significance of hypertension in this population (Thompson & Pickering, 
2006). ABPM has a better reproducibility than isolated or aggregated pre-dialysis and post-
dialysis blood pressure values (Peixoto et al, 2000). Out-of-office blood pressure 
measurements (home blood pressure or ABPM) are better predictors of target organ damage 
and mortality in patients with essential hypertension and in patients with kidney disease 
(Agarwal et al, 2009a). The reproducibility of blood pressure measurements followed the 
following order: home blood pressure monitoring > ABPM >> pre-dialysis blood pressure > 
post-dialysis blood pressure (Agarwal et al, 2009b). A substantial number of prospective 
studies has shown that ABPM predicts cardiovascular events better than clinic-based 
readings, and also correlates more closely with target organ damage. In many studies a poor 
correlation was found between dialysis center measurements and ABPM readings obtained 
in the interdialytic period (Thompson & Pickering, 2006). In a study performed with ABPM 
in a group of dialysis patients, 44-hour interdialytic ABPM was compared with dialysis 
center measurements taken by a nurse. In that study, 43% of patients classified as 
hypertensive by pre-dialysis systolic blood pressure were normotensive on ABPM, whereas 
25% of patients classified as normotensive by pre-dialysis systolic blood pressure were 
hypertensive (Santos et al, 2003). However, other studies found good agreement between 
average pre-dialysis blood pressure and interdialytic ABPM (Agarwal & Lewis, 2001). 
Changes that occur in ABPM during the interdialytic period likely account for the 
discrepancies with dialysis center measurements found in some studies. Conlon et al 
averaged dialysis center measurements from multiple visits and showed that pre-dialysis 
blood pressures averaged over 12 treatment sessions showed a strong correlation with 
ABPM (Conlon et al, 1996). Based on the results of 48-h ABPM in 36 hemodialysis patients, 
Coomer et al developed a model to predict mean blood pressure based on age, sex, race, and 
pre- and post-dialysis blood pressure (Coomer et al, 1997). Agarwal and Lewis compared 
ABPM with a 2-week average of dialysis center measurements in 70 dialysis patients and 
found that a 2-week average cutoff pre-dialysis blood pressure of 150/80 mmHg or higher 
had 80% sensitivity and 67% specificity to detect interdialytic hypertension as defined by an 
average ambulatory blood pressure of 135/85 mmHg or higher (Agarwal & Lewis, 2001).  
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Although these methods can be used to obtain a better estimate of interdialytic control, they 
cannot reliably determine blood pressure in any individual patient. Home blood pressure 
monitoring and standardized predialysis blood pressure measurements can aide in the 
assessment of blood pressure control. In a prospective cross-sectional study, home blood 
pressures averaged over one week were shown to be superior to routine dialysis center 
measurements averaged over 2 weeks in predicting hypertension on 44-h ABPM. 
Standardized pre-dialysis blood pressure averaged over 2 weeks had similar predictive 
ability as home measurements (Agarwal et al, 2006b). ABPM is superior to dialysis center 
blood pressure measurements in predicting target organ damage in patients with ESRD 
(Thompson & Pickering, 2006). In one of the largest study to date 44-h ABPM and home 
blood pressure monitoring, although weak determinants of left ventricular hypertrophy, 
were superior to a 2-week average of standardizes and routine dialysis center measurements 
in 140 chronic hemodialysis patients (Agarwal et al, 2006c). The correlation between left 
ventricular hypertrophy and blood pressure was similar using ABPM and an average of 12 
standardized pre-dialysis measurements in a study of 35 stable hemodialysis patients 
(Conlon et al, 1996). In last decade, a few studies have assessed the prognostic power of 
ABPM and outcomes in hemodialysis patients (Amar et al, 2000, Liu et al, 2003, Tripepi et al, 
2005, Agarwal et al, 2007, Moriya et al, 2008, Agarwal, 2010). In all these four studies ABPM 
contain greater prognostic information compared to blood pressure measurements in the 
dialysis center. The use of out-of-office blood pressure measurement techniques including 
self-measured blood pressure and ABPM in the management of hemodialysis patients is 
increasing. In the general population, blood pressure falls on average by 10-20% during 
sleep, a phenomen reffered to as »dipping«. In about 25% of healthy subjects, and in certain 
disease states, however, a loss in diurnal variation in blood pressure has been reported (non-
dipping) (Thompson & Pickering, 2006). Non-dipping is particularly common in both 
children and adults with CKD, and an inverse relationship between GFR and the prevalence 
of non-dipping has been described (Farmer et al, 1997). Although the reported prevalence of 
non-dipping in adults with CKD varies, rates of 50% or higher have been observed at the 
earliest stages of disease, whereas rates of more than 80% have been observed in patients on 
dialysis (Farmer et al, 1997). A loss of diurnal variation in blood pressure has been 
associated with a poor renal prognosis and linked to left ventricular hypertrophy, adverse 
cardiovascular outcomes, and all-cause mortality in patients with ESRD. In a study of 59 
hemodialysis patients, a correlation was found between the day/night ratio and left 
ventricular mass index (Rahman et al, 2005). In a cohort of 80 dialysis patients without a 
history of congestive heart failure or significant cardiovascular disease, non-dipping status 
was associated with an increased adjusted hazard ratio for cardiovascular morbidity and 
mortality (Liu et al, 2003). A study of 57 hypertensive ESRD patients without a history of 
systolic cardiac disfunction or valvular disease found that after controlling for age, sex, and 
cardiovascular history, an elevated nocturnal blood systolic blood pressure was associated 
with increased cardiovascular mortality (Amar et al, 2000). In a study by Tripepi et al, 168 
dialysis patients without a history of diabetes, cardiovascular disease, or clinical evidence of 
heart failure were followed for 38 months. In a multi-regression analysis model not 
including left ventricular hypertrophy, an association between the highest night/day blood 
pressure tertile and increased cardiovascular and all-cause mortality was found. In contrast, 
the predialysis blood pressure averaged over one month did not predict events (Tripepi et 
al, 2005). Why this loss of nocturnal variation carries such a poor prognosis is unknown. It is 
possible that the absence of a nocturnal decline in blood pressure is not itself a cause of 
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adverse outcomes, but is instead just a marker of sicker patients. In the meantime, 
ambulatory or some form of home blood pressure monitoring should be used to obtain a 
more accurate picture of blood pressure control in patients with ESRD. Clinic blood 
pressures frequently under- or overestimate the true blood pressure in CKD patients and 
dialysis center blood pressure measurements, although widely used to guide therapy, are 
poor indicators of interdialytic blood pressures.         
5. Cardiovascular changes in hemodialysis hypertension 
The association between uraemia and an increased risk of cardiovascular disease was first 
documented by Lindner (Lindner et al, 1974). Cardiovascular disease is the leading cause of 
morbidity and mortality in patients with ESRD (Guerin et al, 2006). Compared to the general 
population the annual cardiovascular death rate in dialysis patients is higher for all age 
groups, though particularly for the young whose mortality is up to 100 times greater than 
the general population. The average life expectancy of patients with ESRD is approximately 
5 years, regardless of the modality of dialysis. Most patients with ESRD have a higher 
prevalence of traditional and also nontraditional cardiovascular disease risk factors when 
compared to the general population. The associations between traditional cardiovascular 
disease risk factors and atherosclerosis such as age, diabetes mellitus, hypertension, 
smoking, obesity, and dyslipidemia have been well described in dialysis patients. Cardiac 
deaths account for the majority of cardiovascular deaths in dialysis patients. The exact 
etiologies of these cardiac deaths are often unknown and likely include primary and 
secondary arrhythmias, cardiomyopathy, and coronary artery disease, and involve complex 
pathogenes. Although fluid overload, increased afterload from hypertension and vascular 
calcification, calcified valvular disease, and ischemia are probably important contributory 
factors, uremia per se seems to be an additional factor. To what extend hyperkalemia and 
hypokalemia, frequently present in this patients, contribute to the high incidence of sudden 
death in dialysis patients is not certain, but recent papers suggested the greater danger of 
hypokalemia (Karnik et al, 2001, Herzog et al, 2008,). Hypertension is a frequent finding in 
all stages of CKD. Because the pathogenesis of atherosclerosis in patients with CKD is 
multifactorial, it has been difficult to ascertain the precise role of hypertension in its 
development. Hypertension increases nearly linearly as renal function falls, and the vast 
majority of patients with significant renal failure present with high blood pressure. Blood 
pressure control is of paramount importance in slowing the progression of CKD toward 
ESRD, and also decreasing cardiovascular risk in these patients. Adequate blood pressure 
control should be a major objective in the management of patients with CKD in both the 
earlier and late stages. Uncontrolled hypertension in pre-ESRD patients is an important 
predictor for cardiovascular mortality during ESRD. More than 80% of patients have a 
history of hypertension, and more than two-thirds of these are uncontrolled (Agarwal et al, 
2003). Foley et al found in a study with 432 hemodialysis patients that high blood pressure 
during dialysis therapy was associated with several adverse outcomes, including concentric 
left ventricular hypertrophy, left ventricular dilatation, ischemic heart disease and cardiac 
failure (Foley et al, 1996). They found an inverse association between average blood 
pressure level while on dialysis and mortality. Low blood pressure was associated with 
earlier death independently of age, diabetes, ischemic heart disease, anemia and 
hypoalbuminemia. There was an inverse relationship between average blood pressure and 
mortality (Foley et al, 1996). Port et al in a study of 4499 hemodialysis patients found the 
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association of a low pre-dialysis systolic blood pressure with an elevated adjusted mortality 
risk (relative mortality risk = 1.86 for systolic blood pressure < 110 mmHg, P < 0.0001) (Port 
et al, 1999). A »U-shaped« curve (Figure 4) exists between blood pressure level and 
mortality in hemodialysis patients, with higher mortality noted at lower levels of blood 
pressure <120 mmHg and levels >180 mmHg measured before hemodialysis (Zager et al, 
1998, Port et al, 1999, Kalantar-Zadeh et al, 2005, Luther & Golper, 2008, Hopkins & Bakris, 
2009b). An analysis based on the CREED study cohort adjusted for Framingham risk factors, 
background cardiovascular complication, and left ventricular mass and ejection fraction 
shows that the risk of death is lowest in dialysis patients with a pre-dialysis systolic blood 
pressure between 100 and 125 mmHg (Zager et al, 1998), whereas systolic blood pressure > 
150 mmHg was associated with increased mortality (Zoccali, 2003). Both post-dialysis 
systolic blood pressure ≥ 180 mmHg and diastolic blood pressure ≥ 90 mmHg were 
associated with a substantial increase in cardiovascular mortality (Zager et al, 1998). Severe 
cardiomyopathy modifies the relationship between blood pressure and mortality, and 
survival is very low in ESRD patients with systolic blood pressure < 115 mmHg (Klassen et 
al, 2002, Li et al, 2006).  
 
 
Fig. 4. Basic relationship of blood pressure to mortality in dialysis patients, as obtained from 
observational studies (Luther & Golper, 2008). 
In an observational study in incident hemodialysis patients pre-dialysis systolic blood 
pressure ≥ 200 mmHg was associated with increased mortality or cardiovascular events (Li 
et al, 2006). Therefore, pre-dialysis blood pressure above this level should be treated 
aggressively. It is assumed, that carotid intima media thickness (IMT) is mirror for general 
atherosclerosis. IMT and plaque occurrence in the carotid arteries are strong predictors for 
cardiovascular events in the general population (Burke et al, 1995). B-mode ultrasound 
imaging is a useful and noninvasive tool to directly quantitate the atherosclerotic burden 
(Kato et al, 2003). Hemodialysis patients are known to have an advanced carotid IMT 
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compared with age- and gender-matched normal controls (Kato et al, 2003). We performed 
the study in which determined that carotid IMT, measured with high resolution B-mode 
ultrasound, may be usefully applied for cardiovascular mortality risk stratification in non-
diabetic HD patients (Ekart et al, 2005). Ninety-nine  non-diabetic hemodialysis patients 
were included in the study. During a follow-up of 42.4  19.5 months (from 12 to 76 months) 
33 patients died, 19 (57.6 %) of them of cardiovascular causes (myocardial infarction, sudden 
cardiac death, heart failure, cerebrovascular insult). In these patients IMT values of the 
common carotid arteries was significantly higher (0.89 vs 0.69 mm; P < 0.0001) than in those 
who survived. Correlation between cardiovascular mortality and IMT was also found (r = 
0.433; P < 0.001). Hemodialysis patients were divided in relationship to the tertiles of IMT 
and the survival rates were analyzed using Kaplan-Meier curves (Figure 5).The risk for 
cardiovascular death was progressively higher from the first tertile of IMT onward (log rank 
test; P < 0.0006). In a Cox regression model that included calcium, phosphate, intact 
parathyroid hormone (iPTH), duration of dialysis treatment, smoking, presence of 
hypertension, cholesterol (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-
density lipoprotein (HDL) cholesterol), triglycerides and lipoprotein (a), IMT turned out to 
be an independent predictor of cardiovascular death (P < 0.025). Our results suggest that 
measurement of IMT thickness in patients with ESRD could be a good predictor for the risk 
of cardiovascular event and also for cardiovascular death (Ekart et al, 2005).  
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Fig. 5. Hemodialysis patients (N=99) were divided in relationship to the tertiles of IMT: I 
tertile, <0.65 mm; II tertile,  0.65 and < 0.8 mm; III tertile,  0.8 mm. Survival rates were 
analyzed using Kaplan-Meier curves. (Ekart et al, 2005). 
We also performed a cross-sectional study in which we assess the relationship between 
carotid IMT as a marker of asymptomatic atherosclerosis and blood pressure measurements 
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obtained with a standard mercury sphygmomanometer before and after the hemodialysis 
session, the average one-monthly values of the routine blood pressure measurements and 
24- and 48-hour ABPM (Ekart et al, 2009). Hypertension was defined as systolic blood 
pressure of 140 mmHg (ABPM ≥ 135 mmHg), diastolic blood pressure of ≥ 90 mmHg 
(ABPM ≥ 85 mmHg) and/or also lower levels if the patient was taking antihypertensive 
drugs. In 85 hemodialysis patients we found statistically significant correlation between 
carotid IMT and average one-monthly pre-hemodialysis diastolic blood pressure (P<0.05), 
diastolic blood pressure on the hemodialysis day ABPM, interdialytic day ABPM and 48-
hour ABPM (P<0.05). We also found a high prevalence of uncontrolled blood pressure 
despite treatment with antihypertensive drugs (Figure 6). The possible reason for 
uncontrolled hypertension in hemodialysis patients is probably bad compliance and 
withholding antihypertensive drugs on the hemodialysis day. Using multiple regression 
analysis we found statistically significant correlation only between carotid IMT and diastolic 
blood pressure on the hemodialysis day ABPM, interdialytic day ABPM and 48-hour ABPM 
(P<0.05). It is important that carotid IMT correlated only with long-term blood pressure 
measurements (one-monthly, 24- and 48-hour ABPM). Isolated systolic hypertension was 
more prevalent compared with isolated diastolic hypertension. It was interesting finding 
about casual connection between carotid IMT and values of diastolic blood pressure on the 
hemodialysis day ABPM, interdialytic day ABPM and 48-hour diastolic blood pressure 
values (Ekart et al, 2009).   
 
 
Fig. 6. Prevalence of uncontrolled hypertension in hemodialysis patients (N=85): different 
blood pressure measurements and not regarding treatment with antihypertensive drugs; 
HD=hemodialysis; (Ekart et al, 2009). 
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The complex pathogenesis of hypertension in hemodialysis patient explains the difficulty of 
its treatment. Management of blood pressure in hemodialysis population requires both 
generally applicable plans and individualization in order to determine the blood pressure 
target and the treatment regimen. For patients with essential hypertension, CKD not yet on 
dialysis, and those with diabetes mellitus, clear guidelines on blood pressure targets exist. 
There are no such guidelines for ESRD patients on hemodialysis. The reason is because no 
randomized controlled trials have been performed in this patients to demonstrate the 
advantages of a given blood pressure target. Very low blood pressure in these individuals 
may make them intolerant to the hemodynamic stress of hemodialysis. An ideal blood 
pressure for a dialysis patient is the lowest that ensures hemodynamic stability during 
dialysis as well as orthostatic tolerance immediately postdialysis and is associated with 
good health-related quality of life. Such a blood pressure should also be associated with the 
lowest cardiovascular morbidity and mortality. A single blood pressure target may not be 
appropriate for all hemodialysis patients. Those patients who are older, who have vascular 
disease, and those with underlying diabetes may have different blood pressure goals than 
those with more pliable circulations and little or no left ventricular hypertrophy. Even 
though blood pressure targets are not defined for hemodialysis patients, most clinicians 
agree that treatment of high blood pressure is warranted. It seems that reaching a pre-
dialysis blood pressure in the range of 130-160 mmHg/80-100 mmHg is safe and advisable 
(Peixoto & Santos, 2010).  
6.1 Control of volume status 
Whatever the target chosen, the strategies should focus first on management of salt and 
water balance, as control of extracellular fluid volume is associated with better blood 
pressure control (Katzarski et al, 1999). This includes dietary sodium restriction 
(Kayikcioglu et al, 2009), increased ultrafiltration and closer attention to the dialysate 
sodium prescription. The control of overhydration in ESRD patients is also of primary 
importance. The absolute content of total body water and sodium must be at level that does 
not cause signs and symptoms of volume overload, including hypertension and signs and 
symptoms of sodium and water depletion, such as dizziness and hypotension. The primary 
goal in the treatment of hypertension should be to attain a dry-weight. In the Tassin 
experience, the »dry weight method«, must be applied and is efficient to correct 
hypertension in these patients. Avoidance of large weight gains in the interdialytic period is 
desirable. To achieve this goal, patients should adhere to a restricted salt diet (750-1000 mg 
os sodium per day), which also helps decrease thirst (Mailloux, 2000, Locatelli et al, 2004). 
The clinician must define the dry weight and goal blood pressure for each dialysis patients 
based upon his or her best judgment. In attempting to achieve dry weight, particularly in 
incident patients starting dialysis, clinicians should me mindful also of the lag in time (from 
several weeks to months) between correction of extracellular volume and hypertension 
(Charra  et al, 1998). The lag phenomenon reflects the time required to convert the patient 
from a catabolic to an anabolic state, a period in which extracellular fluid space slowly 
stabilizes (Charra et al, 1998). Two other factors may limit the degree of fluid removal by 
predisposing to episodes of hypotension during the hemodialysis procedure: 
antihypertensive drugs; and rapid fluid removal required by shorter dialysis times. Thus, 
tapering drug therapy and gradual fluid removal may be beneficial in patients in whom 
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hypotension during dialysis prevents the attainment of dry weight and a normal blood 
pressure. 
6.2 Prolonged and or more frequent hemodialysis 
Longer and/or more frequent dialysis results in better blood pressure control both in 
observational studies and in clinical trials (Walsh et al, 2005, Chan, 2009). In most programs 
of long daily hemodialysis, 80-95% of patients are normotensive without medications. 
Patients in a dialysis center in Tassin, France and some home hemodialysis patients undergo 
long, slow hemodialysis in which the standard regimen is eight hours, three times per week. 
This regimen is associated with the maintenance of normotension without medications in 
allmost all patients (Charra et al, 1992, Covic et al, 1999, McGregor et al, 1999). Although 
these results have been largely attributed to optimal volume control, other factors may also 
contribute, such as more complete control of uremia (Chazot et al, 1995), which may 
decrease afferent renal nerve activity and efferent sympathetic activation (Converse et al, 
1992). A subset of these patients are normotensive despite the presence of increased 
extracellular fluid volume while having achieved clinical dry weight (Katzarski et al, 1999). 
Nocturnal hemodialysis, procedure in which dialysis is performed six or seven nights a 
week during sleep for a variable amount of time based upon the length of sleep desired 
(usually 6 to 12 hours in total), is also associated with excellent blood pressure control 
(Agarwal, 2003). Allmost all patients become normotensive without medications. To achieve 
this, the »target weight« is progressively decreased until all antihypertensive agents are 
discontinued (Henrich & Mailloux, 2010). Some studies also suggest that more frequent 
hemodialysis treatments, via short daily hemodialysis, may also be associated with 
normotension without medications and with regression of left ventricular hypertrophy 
(Henrich & Mailloux, 2010). The 2007 European Best Practice Guidelines recommend that 
the treatment  time and/or frequency of dialysis should be increased in patients with 
hypertension despite optimal volume removal (Tattersall et al, 2007). The prescription of 
longer and/or more frequent hemodialysis sessions allows the decrease in ultrafiltration 
rate and reduces the risk of intradialytic complications (Brunet et al, 1996, Laurent & Charra, 
1998, Okada et al, 2005). 
6.3 Dialysate sodium management 
Achievement of adequate extracellular fluid volume requires not only assessment of dry 
weight and ultrafiltration, but also minimization of exposure to sodium. This occurs by 
dietary salt restriction and optimization of the dialysate sodium prescription. Most 
hemodialysis patients have serum sodium levels that are lower than normal and have a 
relatively fixed set points at these lower levels (Peixoto et al, 2010). Because of these lower 
serum sodium levels, approximately two-thirds of patients will have a high dialysate-to-
plasma sodium gradient if dialyzed against a typical dialysate sodium concentration of 140 
mmol/l (Santos & Peixoto, 2008). This unfavorable gradient leads to decreased sodium 
dialysance, which contributes to sodium overload (Peixoto & Santos, 2010). Use of lower 
dialysate sodium levels (134-136 mmol/l) results in increased sodium removal (Manlucu et 
al, 2010) and, in most but not in all studies, better blood pressure control (Thein et al, 2007, 
Santos & Peixoto, 2010, Manlucu et al, 2010). This effect is the result of a modest (~10%) 
decrease in the extracellular to intracellular water volume ratio (Manlucu et al, 2010) and a 
33% fall in peripheral vascular resistence (Farmer et al, 2000). However, indiscriminate 
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decreases in dialysate sodium may lead to hemodynamic instability and cramping in those 
patients whose baseline serum sodium is 140 mmol/l or higher. Therefore, individualizing 
the dialysate prescription to the patient`s own serum sodium is a preferable approach that 
results in decreased thirst, interdialytic weight gain and blood pressure without causing any 
increase in dialysis-related symptoms (De Paula et al, 2004). Attention to the prescribed 
dialysate sodium level is an essential part of achieving volume control in hemodialysis 
patients. Lowering the dialysate sodium level to match the patient`s own serum sodium is 
an effective means of accomplishing this goal. 
6.4 Antihypertensive drugs 
The majority of patients with ESRD on chronic dialysis undergoing standard thrice weekly 
treatment need antihypertensive drug therapy (Agarwal et al, 2003). Several observational 
studies have suggested that the use of antihypertensive drugs is associated with improved 
survival (Salem & Bower, 1996, Zager et al, 1998). Furthermore, among antihypertensive 
drugs, beta blockers have been reported to be associated with improved outcomes in 
observational studies (Foley et al, 2002). Therefore it appears that the use of 
antihypertensive drugs at least does not increase mortality among hemodialysis patients. 
Drug therapy for hypertension in hemodialysis patients includes all classes of 
antihypertensive drugs, but only selected patients may benefit from loop diuretic therapy 
(Hörl & Hörl, 2004). In addition to their antihypertensive effects, some drugs are variably 
cardioprotective, which may be independent of their blood pressure-lowering effects. The 
meta-analysis by Agarwal and Sinha showed a cardiovascular benefit for hypertensive 
hemodialysis patients from blood pressure lowering unlike what is suggested by 
observational studies (Agarwal & Sinha, 2009). However, the possibility that the benefits of 
antihypertensive drugs used in hemodialysis patients were because of non-hemodynamic 
actions is not ruled out. Pharmacokinetics of antihypertensive and putative cardioprotective 
drugs are altered by both impaired kidney excretion of the drugs and by their dializability. 
The multitude of drugs that these patients usually take reduces compliance, because of 
tolerability, interactions with other drugs, side effects, and financial costs (Schmid et al, 
2009). Pharmacotherapy to lower blood pressure may cause additional problems that are 
unique to dialysis patients, such as intradialytic hypotension and vascular access 
thrombosis. The selection of antihypertensive drugs should be guided by considering their 
comorbidities, pharmacokinetics, and hemodynamic effects. For example, in patients with 
left ventricular hypertrophy, angiotensin converting enzyme (ACE) inhibitors may be 
effecting in causing regression (Paoletti et al, 2002). Hemodialysis patients may be more 
prone to side effects of certain drugs than patients with earlier stages of CKD. The presence 
of and propensity to these side effects may be easily overlooked. For example, minoxidil 
may potentiate or be confused with uremic pericardial effusion (Levin et al, 2010). A 2009 
systematic review and meta-analysis of eight randomised controlled trials (three with and 
five without hypertensive patients) that enrolled 1679 dialysis patients found that lowering 
blood pressure with antihypertensive therapy was associated with decreased risks of 
cardiovascular events (RR of 0.71, 95% CI 0.55-0.99), all cause mortality (RR 0.80, 0.66-0.96) 
and cardiovascular mortality (0.71, 0.50-0.99) (Heerspink et al, 2009). Although there was 
significant variation in attained blood pressure, the overall mean decrease in systolic and 
diastolic blood pressure with active therapy was 4 to 5 mmHg and 2 to 3 mmHg, 
respectively. There were no studies that compared the efficacy of different antihypertensive 
agents. Additional limitations included the low number of patients, lack of information 
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concerning volume control, and marked variations in blood pressure reduction (Tomson, 
2009). Despite these limitations, it generally appears that renin-angiotensin-system blockers, 
beta blockers, and calcium-chanell blockers provide similar efficacy in dialysis patients. 
Recommendations on antihypertensive drugs are usually based on their efficacy in blood 
pressure reduction, interdialytic and intradialytic pharmacokinetics, side-effect profile, 
independent cardioprotective effects and non-cardiovascular effects of the specific class, as 
well as on the comorbidities of the patient. Calcium-chanell blockers are both effective and 
well tolerated in dialysis patients, even in those who are volume expanded (London et al, 
1990). The only randomized prospective study found, that amlodipine, compared with 
placebo, improved overall mortality among hypertensive dialysis patients (Tepel et al, 2008). 
Calcium-channel blockers are particularly useful in patients with left ventricular 
hypertrophy and diastolic dysfunction. Calcium-channel blockers do not require 
supplementary postdialysis dosing. ACE inhibitors are well tolerated and are particularly 
effective in patients with heart failure due to systolic dysfunction and in many patients after 
myocardial infarction. The 2006 K/DOQI guidelines also suggest that ACE inhibitors 
and/or angiotensin II receptor blockers (ARB) are preferred in dialysis patients with 
significant residual renal function (K/DOQI, 2006).  These agents may help preserve native 
kidney function. ACE inhibitors and ARB are associated with a decrease in left ventricular 
mass among hemodialysis patients (Canella et al, 1997, Tai et al, 2010). ARB and ACE 
inhibitors have similar issues in terms of adverse effects, including hyperkalemia and 
possible dampened erythropoiesis (Hörl & Hörl, 2004). Beta blockers are particularly 
indicated in patients who have had a recent myocardial infarction. As in nonuremic subjects, 
ESRD patients who have heart failure due to systolic dysfunction may also benefit from 
therapy with a beta blockers. Such therapy should be initiated at very low doses to minimize 
the risk of hemodynamic deterioration. In addition, beta blockers should be used cautiously 
in patients also taking a calcium-channel blocker, since there are often additive negative 
chronotropic and inotropic actions. 
7. Summary 
Hypertension is common in hemodialysis patients with major implications for survival. 
Accurate measure of blood pressure is an essential precursor for management. Pre- and 
post-dialysis blood pressure measurement may not reflect the average blood pressure 
experienced by the patient. Most management decisions for the diagnosis and treatment of 
hypertension are made using blood pressure measurements made in the dialysis center. 
However, ABPM and home blood pressure recordings may be of superior prognostic value. 
They are generally superior to the dialysis center blood pressure measurements in 
predicting long-term prognosis. In addition, ABPM and home blood pressure recordings 
significantly and strongly predict cardiovascular events. The reference standard for 
diagnosing hypertension among hemodialysis patients is 44-48 hour interdialytic 
ABPM. Hypervolemia that is not clinically obvious is the most common treatable cause of 
hypertension among patients with ESRD; thus, volume control should be the initial therapy 
to treat hypertension in most hemodialysis patients. Reducing dietary and dialysate sodium 
is an often overlooked strategy to improve blood pressure control. The treatment should be 
guided by blood pressure obtained outside the dialysis center. In general, all 
antihypertensive drugs can be used in the hemodialysis population with doses determined 
by dialyzability and hemodynamic instability. Renin-angiotensin-aldosterone system 
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inhibitors have been shown to improve cardiovascular morbidity and mortality and are 
recommended as the initial pharmacologic therapy for hypertensive hemodialysis patients. 
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interesting findings in dealing with patients suffering of other diseases simultaneously, such as diabetes,
cardiovascular disease and other health problems. Each chapter has been thoroughly revised and updated so
the readers are acquainted with the latest data and observations in these complex cases, where several
aspects are to be considered. The book is comprehensive and not limited to a partial discussion of
hemodialysis. To accomplish this we are pleased to have been able to summarize state of the art knowledge in
each chapter of the book.
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